These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34708307)

  • 1. Clinical features and risk factors for early recurrence after esophagectomy following neoadjuvant chemotherapy for esophageal cancer.
    Kurogochi T; Honda M; Takahashi K; Okamura A; Imamura Y; Yamashita K; Kamiya S; Hayami M; Mine S; Watanabe M
    Surg Today; 2022 Apr; 52(4):660-667. PubMed ID: 34708307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma.
    Yoshida N; Baba Y; Shigaki H; Harada K; Iwatsuki M; Sakamoto Y; Miyamoto Y; Kurashige J; Kosumi K; Tokunaga R; Watanabe M; Baba H
    Int J Clin Oncol; 2016 Dec; 21(6):1071-1078. PubMed ID: 27255393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Significance of Pretherapeutic Serum Squamous Cell Carcinoma Antigen Level in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
    Okamura A; Matsuda S; Mayanagi S; Kanamori J; Imamura Y; Irino T; Kawakubo H; Mine S; Takeuchi H; Kitagawa Y; Watanabe M
    Ann Surg Oncol; 2021 Feb; 28(2):1209-1216. PubMed ID: 32524457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel pathological staging for patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by surgery.
    Oguma J; Ishiyama K; Kurita D; Kanematsu K; Fujii Y; Kubo K; Yamamoto S; Honma Y; Kato K; Daiko H
    Esophagus; 2022 Apr; 19(2):214-223. PubMed ID: 34757482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk prediction of esophageal squamous cell carcinoma recurrence in patients who underwent esophagectomy after receiving neoadjuvant treatment: a nationwide retrospective study in Japan.
    Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y
    Esophagus; 2023 Jul; 20(3):465-473. PubMed ID: 37029845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma.
    Sugase T; Kanemura T; Takeoka T; Matsuura N; Masuike Y; Shinno N; Hara H; Kitakaze M; Kubo M; Mukai Y; Sueda T; Hasegawa S; Akita H; Nishimura J; Wada H; Yasui M; Omori T; Miyata H
    Anticancer Res; 2024 Jan; 44(1):185-193. PubMed ID: 38159967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microscopic venous invasion is a predictor of prognosis in patients with esophageal squamous cell carcinoma undergoing ineffective neoadjuvant chemotherapy and surgery.
    Tanishima Y; Takahashi K; Nishikawa K; Ishikawa Y; Yuda M; Tanaka Y; Matsumoto A; Yano F; Eto K
    Esophagus; 2023 Oct; 20(4):651-659. PubMed ID: 37081314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma.
    Ma S; Yan T; Liu D; Wang K; Wang J; Song J; Wang T; He W; Bai J; Jin L; Chen X
    Thorac Cancer; 2018 Feb; 9(2):310-315. PubMed ID: 29319236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy.
    Oguma J; Ishiyama K; Kurita D; Kanematsu K; Kubo K; Utsunomiya D; Yamamoto S; Honma Y; Kato K; Daiko H
    Esophagus; 2023 Apr; 20(2):215-224. PubMed ID: 36565340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma.
    Nagai Y; Yoshida N; Baba Y; Harada K; Imai K; Iwatsuki M; Karashima R; Koga Y; Nomoto D; Okadome K; Ishimoto T; Imamura Y; Watanabe M; Baba H
    Dig Endosc; 2020 Jan; 32(1):39-48. PubMed ID: 31120560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
    Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
    Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery.
    Kitasaki N; Hamai Y; Emi M; Kurokawa T; Yoshikawa T; Hirohata R; Ohsawa M; Okada M
    In Vivo; 2022; 36(6):2852-2860. PubMed ID: 36309376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Patterns of recurrence in patients with stage pT3N0M0 thoracic esophageal squamous cell carcinoma after two-field esophagectomy].
    Wang Y; Wang L; Yang Q; Li J; He M; Yao J; Qi Z; Li B; Qiao X
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):48-54. PubMed ID: 26796807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Preoperative Platelet to Lymphocyte Ratio Is Associated with a Greater Risk of Postoperative Complications and Hematogenous Recurrences in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Treatment.
    Sasahara M; Kanda M; Shimizu D; Takami H; Inokawa Y; Hattori N; Hayashi M; Tanaka C; Fujiwara M; Nakayama G; Kodera Y
    Dig Surg; 2023; 40(1-2):48-57. PubMed ID: 36893749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of endoscopic response evaluation after neoadjuvant chemotherapy for esophageal squamous cell carcinoma: a nationwide validation study.
    Matsuda S; Kitagawa Y; Okui J; Okamura A; Kawakubo H; Takemura R; Kono K; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y
    Esophagus; 2023 Jul; 20(3):455-464. PubMed ID: 36964333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy for pT1a-m3/pT1b esophageal squamous cell carcinoma after endoscopic resection: Esophagectomy or chemoradiotherapy? A critical review.
    Tsou YK; Lee CH; Le PH; Chen BH
    Crit Rev Oncol Hematol; 2020 Mar; 147():102883. PubMed ID: 32014674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for recurrence of esophageal squamous cell carcinoma after pathological complete response to neoadjuvant therapy followed by esophagectomy.
    Hirohata R; Hamai Y; Emi M; Ibuki Y; Kurokawa T; Ohsawa M; Kitasaki N; Okada M
    World J Surg; 2024 Jul; 48(7):1700-1709. PubMed ID: 38757868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-esophagectomy Adjuvant Chemotherapy Benefits Esophageal Cancer Patients.
    Sohda M; Saito H; Kuriyama K; Yoshida T; Kumakura Y; Honjyo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Sakai M; Miyazaki T; Fukuchi M; Kuwano H
    In Vivo; 2019; 33(2):501-506. PubMed ID: 30804133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Tumor Size on Survival Outcome in Esophageal Squamous Cell Carcinoma After Esophagectomy Following Neoadjuvant Chemotherapy.
    Koterazawa Y; Oshikiri T; Goto H; Kato T; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Kakeji Y
    Ann Surg Oncol; 2024 Apr; 31(4):2482-2489. PubMed ID: 38151622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.